How many drugs treat Cerebrovascular accident?

Drug Landscape tracks 10 marketed treatments for Cerebrovascular accident (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/cerebrovascular-accident.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cerebrovascular accident — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cerebrovascular accident (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Cerebrovascular accident, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zontivity	VORAPAXAR	Key Therap	Protease-activated Receptor-1 Antagonist	Proteinase-activated receptor 1	2014-01-01
Crestor	rosuvastatin	AstraZeneca	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Micardis	TELMISARTAN	Boehringer Ingelheim	Angiotensin 2 Receptor Blocker [EPC]	Type-2 angiotensin II receptor	1998-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Norvasc	amlodipine	Pfizer Inc.	Calcium channel blocker (dihydropyridine)	Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6	1992-07-31
Altace	RAMIPRIL	King Pfizer	Angiotensin Converting Enzyme Inhibitor [EPC]	Angiotensin-converting enzyme	1991-01-01
Zocor	simvastatin	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Amlodipin	Amlodipin	Boehringer Ingelheim		Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6
Pritor	Pritor	DongKoo Bio & Pharma		ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Boehringer Ingelheim · 2 drugs in Cerebrovascular accident
Pfizer Inc. · 2 drugs in Cerebrovascular accident
Key Therap · 1 drug in Cerebrovascular accident
AstraZeneca · 1 drug in Cerebrovascular accident
Merck & Co. · 1 drug in Cerebrovascular accident
Pfizer · 1 drug in Cerebrovascular accident
King Pfizer · 1 drug in Cerebrovascular accident
DongKoo Bio & Pharma · 1 drug in Cerebrovascular accident

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cerebrovascular accident:

Cite this brief

Drug Landscape (2026). Cerebrovascular accident — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cerebrovascular-accident. Accessed 2026-06-10.

Cerebrovascular accident full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing